Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 6, 2002, Pages 303-315

  Hsieh, Michael H ^a   Varadi, Gabor ^a   Flomenberg, Neal ^a   Korngold, Robert ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Allogeneic hematopoietic cell transplantation; Donor lymphocyte infusions; Graft versus host disease; Graft versus leukemia

Indexed keywords

ALLOANTIGEN; DIPEPTIDYL PEPTIDASE I; FAS LIGAND; LEUCYLLEUCINE METHYL ESTER; MITOGENIC AGENT; OVALBUMIN; PERFORIN; DIPEPTIDE; IMMUNOSUPPRESSIVE AGENT; LEUCYL LEUCINE METHYL ESTER; LEUCYL-LEUCINE-METHYL ESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CACHEXIA; CANCER SURVIVAL; CELL INFILTRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DONOR; DOSE RESPONSE; DRUG MECHANISM; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDY; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; HYPOPLASIA; HYPOTHESIS; IMMUNOCOMPETENCE; LETHALITY; LYMPHOCYTE; MALE; MONONUCLEAR CELL; MOUSE; MYELOID LEUKEMIA; NONHUMAN; RISK ASSESSMENT; SPLEEN CELL; SPLEEN DISEASE; SYMPTOMATOLOGY; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECT; DRUG SCREENING; HAPLOTYPE; HISTOCOMPATIBILITY; IMMUNOLOGY; LYMPHOCYTE TRANSFUSION; METHODOLOGY; MORTALITY; PATHOLOGY; RISK; TREATMENT OUTCOME;

ANIMALS; BONE MARROW TRANSPLANTATION; DIPEPTIDES; DRUG EVALUATION, PRECLINICAL; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HAPLOTYPES; HISTOCOMPATIBILITY; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID; LYMPHOCYTE TRANSFUSION; MALE; MICE; MICE, INBRED C57BL; RISK; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0036063860     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm12108916     Document Type: Article

References (49)

1. Perforin and granzyme B: Predictive markers for acute GVHD or cardiac rejection after bone marrow or heart transplantation
2. Immunohistochemical identification of perforin-positive cytotoxic lymphocytes in graft-versus-host disease
3. CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients
4. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation
5. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation
6. Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease
7. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect
8. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice
9. T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic mechanisms
10. Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses
11. Apoptosis is induced in cells with cytolytic potential by l-leucyl-l-leucine methyl ester
12. Lethal graft-vs-host disease across major histocompatibility barriers: Requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells
13. Pretreatment of murine donor grafts with L-leucyl-L-leucine methyl ester: Elimination of graft-versus-host disease without detrimental effects on engraftment
14. Studies of the use of L-leucyl-L-leucine methyl ester in canine allogeneic marrow transplantation
15. Ex vivo purging of allogeneic marrow with L-leucyl-L-leucine methyl ester: A phase I study
16. Characterization of the in vitro sensitivity of human lymphoid and hematopoietic progenitors to L-leucyl-L-leucine methyl ester
17. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
18. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
19. A mouse c-myc retrovirus transforms established fibroblast lines in vitro and induces monocyte-macrophage tumors in vivo
20. An endogenous 55 kDa TNF receptor mediates cell death in a neural cell line
21. Expression of an exogenous tumor necrosis factor (TNF) gene in TNF-sensitive cell lines confers resistance to TNF-mediated cell lysis
22. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation
23. Tumor necrosis factor-related ligands and receptors
24. The role of major histocompatibility complex and non-major histocompatibility complex encoded antigens in generation of bile duct lesions during hepatic graft-vs.-host responses mediated by helper or cytotoxic T cells
25. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease
26. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies
27. Lethal graft-vs-host disease induced by a class II MHC antigen only disparity is not mediated by cytotoxic T cells
28. Prevention of lethal murine graft versus host disease by treatment of donor cells with L-leucyl-L-leucine methyl ester
29. Prevention of murine graft-versus-host disease and bone marrow alloengraftment across the major histocompatibility barrier after donor graft preincubation with anti-LFA1 immunotoxin
30. L-leucyl-L-leucine methyl ester treatment of canine marrow and peripheral blood cells: Inhibition of proliferative responses with maintenance of the capacity for autologous marrow engraftment
31. Failure of recombinant stem cell factor to enhance engraftment of L-leucyl-L-leucine methyl ester treated canine marrow after irradiation
32. The immunosuppressive activity of L-leucyl-L-leucine methyl ester: Selective ablation of cytotoxic lymphocytes and monocytes
33. Effects of L-leucyl-L-leucine methyl ester on human marrow and protection of progenitor cells by IL-1
34. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation
35. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Impact of donor lymphocyte infusion
36. A major role for the Fas pathway in acute graft-versus-host disease
37. Identification and characterization of a new member of the TNF family that induces apoptosis
38. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
39. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells
40. The receptor for the cytotoxic ligand TRAIL
41. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL
42. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages
43. Immune reconstitution following bone marrow transplantation: Comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts
44. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function
45. Immune reconstitution following T-cell depleted bone marrow transplantation: Effect of age and posttransplant graft rejection prophylaxis
46. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions
47. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants
48. Resolution of early cytomegalovirus (CMV) infection after leukocyte transfusion therapy from a CMV seropositive donor